Track topics on Twitter Track topics that are important to you
The objective is to describe the effectiveness, measured by clinical success and the recovery time of symptoms (cough, mucus, fever and sore throat), tolerability and compliance of treatment with Klacid XL once daily in patients with upper or lower respiratory tract infections in the routine clinical practice.
- Time to the resolution of cough and other symptoms. Time to recovery was defined as the number of days required for the patient to return to baseline after initiation of Klacid XL therapy.
- Baseline is defined as the the symptom status prior the onset of RTI. This status is based on the patient & physician assessment. Fast recovery is defined as the resolution of symptoms in less than or equal to 5 days from the start of Klacid XL treatment. Secondary endpoints:
- Adverse Events:record the number, symptoms and severity of adverse events for Klacid XL. The action taken, outcome and relationship to Klacid XL treatment should be addressed.
- Percentage of treatment failure:defined as failure to return to baseline before 10 days or the requirement of new treatments or medications during the first 10 days for persistence or aggravation of symptoms.
- Factors affecting the speed of recovery:identifying variables independently and significantly associated with the speed of recovery.
- Individual Clinical outcomes of treatment:
1. Body temperature (highest temperature; duration of temperature over 37.0 degree of Celsius in days, oral measurement)
2. Cough and its character (present or not; type of cough:productive, irritating; duration; all reported by the patient)
3. Dyspnoea (type of dyspnoea:after exercise, rest; duration; reported by the patient)
4. Auscultation findings (normal, abnormal - wheezing, crackles),
5. Mucus production (yes - disappearance or significant decrease of mucus amount and / or viscosity, no),
6. Adverse Events (no, yes - description),
7. Compliance (treatment was followed in both dosage and duration - yes, no),
8. Termination of treatment (planned, premature - reason).
Observational Model: Cohort, Time Perspective: Retrospective
Respiratory Tract Infection
clarithromycin (Klacid XL)
Not yet recruiting
Published on BioPortfolio: 2014-07-23T21:10:00-0400
The investigators hypothesize that Klacid® MR provides short symptoms' recovery time in Thai patients with upper or lower respiratory tract infections.
Klacid® Granules for Oral Suspension provides short symptoms' recovery time in Thai children with lower respiratory tract infections.
The purpose of the study is to examine whether Klacid® (Clarithromycin) will induce oxidative stress (stress from oxygen) in healthy subjects. This is done by measuring the content of a p...
It is well recognized that respiratory viruses cause substantial disease burden every year. Among all known respiratory viruses, influenza virus is the greatest cause of disability-adjuste...
RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-...
Severe acute lower respiratory tract infection (ALRTI) remains an important cause of childhood morbidity and mortality.
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during the first year of life. Antibiotic treatment is recommended in cases suspected of bacteri...
Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory tract infection in infants. Maternally-derived RSV-specific antibodies play a role in protection against RSV infection...
Porcine bocavirus (PBoV) is a recently discovered virus classified within the Bocavirus genus. We present a case of upper respiratory tract infection associated with PBoV in a three-year-old child who...
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection in vulnerable populations. Natural killer (NK) cells and dendritic cells (DC) are important for the effector function...
An abnormal passage communicating between any component of the respiratory tract or between any part of the respiratory system and surrounding organs.
That part of the RESPIRATORY TRACT or the air within the respiratory tract that does not exchange OXYGEN and CARBON DIOXIDE with pulmonary capillary blood.
Granulomatous disorders affecting one or more sites in the respiratory tract.
Respiratory system manifestations of diseases of the respiratory tract or of other organs.
Methods and procedures for the diagnosis of diseases of the respiratory tract or its organs. It includes RESPIRATORY FUNCTION TESTS.
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...